BMS’ Abecma (idecabtagene vicleucel) Receives the Health Canada’s Approval as the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma

June 1, 2021 Auto Bot Abecma, approval, BMS, Health Canada, Refractory, regulatory, Relapsed 0

Shots:

  • The conditional approval is based on the results of the P-II KarMMa study involves assessing Abecma in 122 patients with RRMM prior treated with 3L+ therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 Ab and who are refractory to their last treatment
  • Results: @median follow-up of 13.3 mos., ORR (74%); CR (32%); mDoR (11mos. who achieved a PR and 19 mos. who achieved a CR); median time to response (1mos.), responses were rapid and durable with a single infusion and safety profile was generally manageable
  • Abecma (idecabtagene vicleucel; ide-cel) is a one-time infusion, first BCMA CAR T cell immunotherapy for adults with MM

Click here to­ read full press release/ article | Ref: Newswire.ca | Image: Fierce Pharma

The post BMS’ Abecma (idecabtagene vicleucel) Receives the Health Canada’s Approval as the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma first appeared on PharmaShots.